Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 15Uterine Cervical Neoplasms 7Endometrial Neoplasms 7Fallopian Tube Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Pancreatic Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Salivary Gland Neoplasms 2Neuroendocrine Tumors 2Lung Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Vulvar Neoplasms 1Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Teratoma 1

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Fanconi Anemia, Complementation Group D1 × Gynecologic × Clear all
NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

AstraZeneca

Phase 2 Completed
265 enrolled 25 charts 1 FDA
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡